TrialBlood advances2026

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.

Shinichi Makita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.